TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-10
鄭安理Cheng, Ann-Lii
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
48筆
41
Chen KH, Lin LI, Tseng LH, Lin YL, Liau JY, Tsai JH, Liang JT, Lin BR, Cheng AL, Yeh KH. CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. Oncology. 2019;96(3):156-163. doi: 10.1159/000493387. Epub 2018 Dec 12. PMID: 30540994.
42
Kuo SH, Wu MS, Yeh KH, Lin CW, Hsu PN, Chen LT, Cheng AL. Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers (Basel). 2019 Apr 17;11(4):547. doi: 10.3390/cancers11040547. PMID: 30999581; PMCID: PMC6520890.
43
Chen YH, Wang CW, Wei MF, Tzeng YS, Lan KH, Cheng AL, Kuo SH. Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer. Cancers (Basel). 2019 Aug 19;11(8):1204. doi: 10.3390/cancers11081204. PMID: 31430901; PMCID: PMC6721476.
44
Liu TH, Shao YY, Lu LC, Shen YC, Hsu C, Lin ZZ, Hsu CH, Cheng AL. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):615-621. doi: 10.1080/17474124.2019.1621165. Epub 2019 May 27. PMID: 31132887.
45
Hsu CY, Wang CW, Cheng AL, Kuo SH. Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectiveness. World J Gastrointest Oncol. 2019 Aug 15;11(8):579-588. doi: 10.4251/wjgo.v11.i8.579. PMID: 31435460; PMCID: PMC6700034.
46
Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer. 2019 Mar;8(2):110-120. doi: 10.1159/000489021. Epub 2018 Jun 15. PMID: 31019901; PMCID: PMC6465685.
47
Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 Feb;14(1):57-65. doi: 10.1007/s11523-019-00620-0. PMID: 30725402; PMCID: PMC6407737.
48
Ou DL, Lin YY, Hsu CL, Lin YY, Chen CW, Yu JS, Miaw SC, Hsu PN, Cheng AL, Hsu C. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer. 2019 May;8(3):155-171. doi: 10.1159/000489318. Epub 2018 Jun 22. PMID: 31192153; PMCID: PMC6547269.
